Correlation Between Alnylam Pharmaceuticals, and DCVY34

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals, and DCVY34 at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals, and DCVY34 into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals, and DCVY34, you can compare the effects of market volatilities on Alnylam Pharmaceuticals, and DCVY34 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals, with a short position of DCVY34. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals, and DCVY34.

Diversification Opportunities for Alnylam Pharmaceuticals, and DCVY34

-0.58

Correlation Coefficient

Alnylam Pharmaceuticals,  DCVY34

Excellent diversification

The 3 months correlation between Alnylam and DCVY34 is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals, and DCVY34 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DCVY34 and Alnylam Pharmaceuticals, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals, are associated (or correlated) with DCVY34. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DCVY34 has no effect on the direction of Alnylam Pharmaceuticals, i.e., Alnylam Pharmaceuticals, and DCVY34 go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals, and DCVY34

Assuming the 90 days trading horizon Alnylam Pharmaceuticals, is expected to generate 0.73 times more return on investment than DCVY34. However, Alnylam Pharmaceuticals, is 1.36 times less risky than DCVY34. It trades about -0.2 of its potential returns per unit of risk. DCVY34 is currently generating about -0.65 per unit of risk. If you would invest  7,540  in Alnylam Pharmaceuticals, on October 13, 2024 and sell it today you would lose (405.00) from holding Alnylam Pharmaceuticals, or give up 5.37% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals,  vs.  DCVY34

Alnylam Pharmaceuticals,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals, has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's essential indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

DCVY34

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in DCVY34 are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, DCVY34 sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Alnylam Pharmaceuticals, and DCVY34

The main advantage of trading using opposite Alnylam Pharmaceuticals, and DCVY34 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals, position performs unexpectedly, DCVY34 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DCVY34 will offset losses from the drop in DCVY34's long position.

The idea behind Alnylam Pharmaceuticals, and DCVY34 pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.